PL369078A1 - Pochodne benzotiazepiny i benzotiadiazepiny mające aktywność hamowania transportu krętniczego kwasów żółciowych (IBAT) do leczenia hiperlipidemii - Google Patents

Pochodne benzotiazepiny i benzotiadiazepiny mające aktywność hamowania transportu krętniczego kwasów żółciowych (IBAT) do leczenia hiperlipidemii

Info

Publication number: PL369078A1
Authority: PL; Poland
Prior art keywords: sup; ibat; bile acid; benzothiazepine; acid transport
Prior art date: 2001-09-08

Application number

PL02369078A

Other languages

English (en)

Other versions

PL216023B1 (pl

Inventor

Ingemar Starke

Mikael Ulf Johan Dahlstrom

David Blomberg

Suzanne Alenfalk

Tore Skjaret

Malin Lemurell

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-08

Filing date

2002-09-05

Publication date

2005-04-18

2001-09-08 Priority claimed from GB0121768A external-priority patent/GB0121768D0/en

2002-04-25 Priority claimed from GB0209463A external-priority patent/GB0209463D0/en

2002-09-05 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-04-18 Publication of PL369078A1 publication Critical patent/PL369078A1/pl

2014-02-28 Publication of PL216023B1 publication Critical patent/PL216023B1/pl

Links

HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 2
208000031226 Hyperlipidaemia Diseases 0.000 title abstract 2
239000003613 bile acid Substances 0.000 title abstract 2
KAOYLRLQZXRRBD-UHFFFAOYSA-N 1,2,3-benzothiadiazepine Chemical class S1N=NC=CC2=CC=CC=C12 KAOYLRLQZXRRBD-UHFFFAOYSA-N 0.000 title 1
FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 2
239000012453 solvate Substances 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Oncology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL369078A 2001-09-08 2002-09-05 Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny PL216023B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0121768A GB0121768D0 (en)	2001-09-08	2001-09-08	Chemical compounds
GB0209463A GB0209463D0 (en)	2002-04-25	2002-04-25	Chemical compounds

Publications (2)

Publication Number	Publication Date
PL369078A1 true PL369078A1 (pl)	2005-04-18
PL216023B1 PL216023B1 (pl)	2014-02-28

Family

ID=26246524

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL369078A PL216023B1 (pl)	2001-09-08	2002-09-05	Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny

Country Status (28)

Country	Link
US (1)	US7132416B2 (pl)
EP (1)	EP1427423B9 (pl)
JP (2)	JP3616635B2 (pl)
KR (1)	KR100935623B1 (pl)
CN (1)	CN1582151A (pl)
AR (1)	AR037089A1 (pl)
AT (1)	ATE349214T1 (pl)
AU (1)	AU2002329387B2 (pl)
BR (1)	BRPI0212346B1 (pl)
CA (1)	CA2459449C (pl)
CO (1)	CO5570671A2 (pl)
CY (1)	CY1106348T1 (pl)
DE (1)	DE60217136T2 (pl)
DK (1)	DK1427423T5 (pl)
ES (1)	ES2278045T3 (pl)
HU (1)	HU227623B1 (pl)
IL (2)	IL160691A0 (pl)
IS (1)	IS7170A (pl)
MX (1)	MXPA04002179A (pl)
MY (1)	MY131995A (pl)
NO (1)	NO327041B1 (pl)
NZ (1)	NZ531796A (pl)
PL (1)	PL216023B1 (pl)
PT (1)	PT1427423E (pl)
RU (1)	RU2305681C2 (pl)
TW (1)	TWI331143B (pl)
UY (1)	UY27436A1 (pl)
WO (1)	WO2003022286A1 (pl)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0000772D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
EG26979A (en)	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
SE0104333D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en) *	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
PL375074A1 (pl) *	2002-06-20	2005-11-14	Astrazeneca Ab	orto-Podstawione pochodne kwasu benzoesowego do leczenia insulinooporności
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en) *	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
AU2008202120B2 (en) *	2003-04-05	2009-12-17	Albireo Ab	Use of an IBAT inhibitor for the treatment of prophylaxis of constipation
GB0314131D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
AR057828A1 (es) *	2005-09-29	2007-12-19	Astrazeneca Ab	Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US7528448B2 (en) *	2006-07-17	2009-05-05	E.I. Du Pont De Nemours And Company	Thin film transistor comprising novel conductor and dielectric compositions
US8062824B2 (en)	2006-07-17	2011-11-22	E. I. Du Pont De Nemours And Company	Thermally imageable dielectric layers, thermal transfer donors and receivers
AU2008221673B2 (en) *	2007-03-08	2013-03-28	Albireo Ab	2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
US7666567B2 (en)	2007-10-23	2010-02-23	E. I. Du Pont De Nemours And Company	Negative imaging method for providing a patterned metal layer having high conductivity
US7666568B2 (en) *	2007-10-23	2010-02-23	E. I. Du Pont De Nemours And Company	Composition and method for providing a patterned metal layer having high conductivity
CA2744817C (en) *	2008-11-26	2020-07-07	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of obesity and diabetes
EP2575821B1 (en) *	2010-05-26	2015-08-12	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
PL3400944T3 (pl)	2010-11-04	2020-11-16	Albireo Ab	Inhibitory ibat w leczeniu chorób wątroby
JP6097695B2 (ja)	2010-11-08	2017-03-15	アルビレオアクチエボラグ	Ｉｂａｔ阻害剤および胆汁酸結合剤を含む薬学的組み合わせ
MX2013005110A (es) *	2010-11-08	2013-08-21	Albireo Ab	Inhibidores del ibat para el tratamiento de padecimientos metabolicos y condiciones relacionadas.
US20120114588A1 (en) *	2010-11-08	2012-05-10	Albireo Ab	Ibat inhibitors for treatment of metabolic disorders and related conditions
CN104023727B (zh) *	2011-10-28	2017-04-05	鲁美纳医药公司	用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CA2852957C (en)	2011-10-28	2020-08-04	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN105228615A (zh)	2013-03-15	2016-01-06	鲁美纳医药公司	用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
US20140275090A1 (en)	2013-03-15	2014-09-18	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar)	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en)	2014-06-25	2015-12-30	Ea Pharma Co., Ltd.	Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
RU2750937C2 (ru)	2016-02-09	2021-07-06	Альбирео Аб	Пероральный состав холестирамина и его применение
EP3413877B1 (en)	2016-02-09	2021-04-07	Albireo AB	Oral cholestyramine formulation and use thereof
US10441604B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en)	2016-02-09	2020-09-29	Albireo Ab	Oral cholestyramine formulation and use thereof
US10441605B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Oral cholestyramine formulation and use thereof
JP2020530448A (ja)	2017-08-09	2020-10-22	アルビレオ・アクチボラグ	コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CA3071182A1 (en)	2017-08-09	2019-02-14	Albireo Ab	Cholestyramine pellets, oral cholestyramine formulations and use thereof
TWI822738B (zh) *	2018-03-09	2023-11-21	瑞典商依洛比克斯公司	用於製備1,5-苯并噻氮呯化合物之方法
US10428109B1 (en)	2018-03-09	2019-10-01	Elobix Ab	Process for the preparation of 1,5-benzothiazepine compounds
ES2942443T3 (es)	2018-06-05	2023-06-01	Albireo Ab	Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US10793534B2 (en)	2018-06-05	2020-10-06	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
BR112020024479A2 (pt) *	2018-06-20	2021-03-02	Albireo Ab	hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10941127B2 (en)	2019-02-06	2021-03-09	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
ES2955799T3 (es)	2019-02-06	2023-12-07	Albireo Ab	Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares
HUE060905T2 (hu) *	2019-02-06	2023-04-28	Albireo Ab	Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként
US10975045B2 (en)	2019-02-06	2021-04-13	Aibireo AB	Benzothiazepine compounds and their use as bile acid modulators
PL3923943T3 (pl)	2019-02-12	2024-12-09	Mirum Pharmaceuticals, Inc.	Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych
JP7689076B2 (ja) *	2019-09-09	2025-06-05	Ｅａファーマ株式会社	１，５－ベンゾチアゼピン化合物を製造するための方法
TWI877262B (zh)	2019-12-04	2025-03-21	瑞典商艾爾比瑞歐公司	苯并噻氮呯化合物及其作為膽酸調節劑之用途
CA3158184A1 (en)	2019-12-04	2021-08-10	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
AR120679A1 (es)	2019-12-04	2022-03-09	Albireo Ab	Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
CA3158181A1 (en) *	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
CN114786772B (zh)	2019-12-04	2024-04-09	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120676A1 (es)	2019-12-04	2022-03-09	Albireo Ab	Compuestos de benzoti(di)azepina y su uso como ácido biliar
ES2973549T3 (es)	2019-12-04	2024-06-20	Albireo Ab	Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
TWI877263B (zh) *	2019-12-04	2025-03-21	瑞典商艾爾比瑞歐公司	苯并噻二氮呯化合物及其作為膽酸調節劑之用途
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
TWI867107B (zh)	2019-12-04	2024-12-21	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
EP4188541B1 (en)	2020-08-03	2024-12-25	Albireo AB	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en)	2020-08-03	2022-02-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022101379A1 (en)	2020-11-12	2022-05-19	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
JP2023549226A (ja)	2020-11-12	2023-11-22	アルビレオエービー	進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
JP2024500309A (ja)	2020-12-04	2024-01-09	アルビレオエービー	ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh)	2021-06-03	2023-04-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2022166680A1 (zh) *	2021-06-25	2022-08-11	苏州科睿思制药有限公司	奥德昔巴特的晶型及其制备方法和用途
WO2023174937A1 (en)	2022-03-16	2023-09-21	Sandoz Ag	Particles comprising non-crystalline odevixibat
JP2025516153A (ja)	2022-04-22	2025-05-27	アルビレオ・アクチボラグ	Ａｓｂｔ阻害剤の皮下投与
KR20250022025A (ko)	2022-06-09	2025-02-14	알비레오 에이비	간염 치료
CN119487013A (zh)	2022-07-05	2025-02-18	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US20240173333A1 (en)	2022-11-03	2024-05-30	Albireo Ab	Treating Alagille Syndrome (ALGS)
EP4630112A1 (en)	2022-12-09	2025-10-15	Albireo AB	Cocrystals of odevixibat
AU2023390975A1 (en)	2022-12-09	2025-06-05	Albireo Ab	Asbt inhibitors in the treatment of renal diseases
WO2024184924A1 (en) *	2023-03-06	2024-09-12	Rk Pharma Inc	"an improved process for the preparation of odevixibat and its crystalline forms"
WO2025093760A1 (en)	2023-11-03	2025-05-08	Albireo Ab	Treating pfic2 with odevixibat
WO2025146507A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4900757A (en)	1988-12-08	1990-02-13	Merrell Dow Pharmaceuticals Inc.	Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
JPH05186357A (ja)	1991-12-31	1993-07-27	Shigeo Ochi	飲食物消化分解産物吸収抑制手段
GB9203347D0 (en)	1992-02-17	1992-04-01	Wellcome Found	Hypolipidaemic compounds
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en)	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
ZA956647B (en)	1994-08-10	1997-02-10	Wellcome Found	Hypolipidaemic compounds.
US5994391A (en)	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DK0781278T3 (da)	1994-09-13	2001-04-17	Monsanto Co	Nye benzothiepiner, som har aktivitet som inhibitorer af ileal galdsyretransport og taurocholatoptagelse
GB9423172D0 (en)	1994-11-17	1995-01-04	Wellcom Foundation The Limited	Hypolipidemic benzothiazepines
NZ331813A (en)	1996-03-11	2001-03-30	G	Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9704208D0 (en)	1997-02-28	1997-04-16	Glaxo Group Ltd	Chemical compounds
MXPA99008417A (es)	1997-03-11	2005-02-03	Searle & Co	Terapia de combinacion que emplaza benzotiepinas inhibidoras de transporte de acido biliar ileal e inhibidores de hmg co-a reductasa.
DE69815180T2 (de)	1997-03-14	2004-04-29	Aventis Pharma Deutschland Gmbh	Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
AUPO763197A0 (en)	1997-06-30	1997-07-24	Sigma Pharmaceuticals Pty Ltd	Health supplement
US6369220B1 (en)	1997-12-19	2002-04-09	Jinglin (James T.) Li	Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides
GB9800428D0 (en)	1998-01-10	1998-03-04	Glaxo Group Ltd	Chemical compounds
DE19825804C2 (de)	1998-06-10	2000-08-24	Aventis Pharma Gmbh	1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PL348508A1 (en)	1998-12-23	2002-05-20	Searle Llc	Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
CN1342090A (zh)	1998-12-23	2002-03-27	G·D·瑟尔有限公司	适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
JP2002533414A (ja)	1998-12-23	2002-10-08	ジー．ディー．サールエルエルシー	心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
EP1140191B1 (en)	1998-12-23	2002-10-23	G.D. Searle LLC.	Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
DE69911058T2 (de)	1998-12-23	2004-06-03	G.D. Searle Llc, Chicago	Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
CA2362147A1 (en) *	1999-02-12	2000-08-17	Steve A. Kolodziej	1,2-benzothiazepines for the treatment of hyperlipidemic diseases
DE19916108C1 (de)	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv)	1999-04-19	1999-04-19	Astra Ab	New pharmaceutical foromaulations
US6287609B1 (en)	1999-06-09	2001-09-11	Wisconsin Alumni Research Foundation	Unfermented gel fraction from psyllium seed husks
AU784722B2 (en)	2000-02-18	2006-06-01	Merck & Co., Inc.	Aryloxyacetic acids for diabetes and lipid disorders
SE0000772D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
AU2001247331A1 (en)	2000-03-10	2001-09-24	Pharmacia Corporation	Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
WO2001068637A2 (en)	2000-03-10	2001-09-20	Pharmacia Corporation	Method for the preparation of tetrahydrobenzothiepines
US20020183307A1 (en)	2000-07-26	2002-12-05	Tremont Samuel J.	Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv)	2000-10-18	2000-10-18	Astrazeneca Ab	Novel formulation
EG26979A (en) *	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
WO2002053548A1 (fr)	2000-12-27	2002-07-11	Banyu Pharmaceutical Co.,Ltd.	Derives de la benzothiazepine
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0201850D0 (en)	2002-01-26	2002-03-13	Astrazeneca Ab	Therapeutic treatment
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en)	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
GB0216321D0 (en)	2002-07-13	2002-08-21	Astrazeneca Ab	Therapeutic treatment
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use

2002
- 2002-09-05 TW TW091120297A patent/TWI331143B/zh not_active IP Right Cessation
- 2002-09-05 CA CA2459449A patent/CA2459449C/en not_active Expired - Lifetime
- 2002-09-05 DK DK02765013.4T patent/DK1427423T5/da active
- 2002-09-05 WO PCT/GB2002/004033 patent/WO2003022286A1/en not_active Ceased
- 2002-09-05 DE DE60217136T patent/DE60217136T2/de not_active Expired - Lifetime
- 2002-09-05 AT AT02765013T patent/ATE349214T1/de active
- 2002-09-05 HU HU0401196A patent/HU227623B1/hu unknown
- 2002-09-05 IL IL16069102A patent/IL160691A0/xx unknown
- 2002-09-05 NZ NZ531796A patent/NZ531796A/en not_active IP Right Cessation
- 2002-09-05 CN CNA028221133A patent/CN1582151A/zh active Pending
- 2002-09-05 JP JP2003526415A patent/JP3616635B2/ja not_active Expired - Lifetime
- 2002-09-05 MX MXPA04002179A patent/MXPA04002179A/es active IP Right Grant
- 2002-09-05 KR KR1020047003407A patent/KR100935623B1/ko not_active Expired - Lifetime
- 2002-09-05 US US10/488,870 patent/US7132416B2/en not_active Expired - Lifetime
- 2002-09-05 PT PT02765013T patent/PT1427423E/pt unknown
- 2002-09-05 ES ES02765013T patent/ES2278045T3/es not_active Expired - Lifetime
- 2002-09-05 PL PL369078A patent/PL216023B1/pl unknown
- 2002-09-05 EP EP02765013.4A patent/EP1427423B9/en not_active Expired - Lifetime
- 2002-09-05 RU RU2004110716/04A patent/RU2305681C2/ru active
- 2002-09-05 BR BRPI0212346A patent/BRPI0212346B1/pt not_active IP Right Cessation
- 2002-09-05 AU AU2002329387A patent/AU2002329387B2/en not_active Expired
- 2002-09-05 MY MYPI20023317A patent/MY131995A/en unknown
- 2002-09-06 AR ARP020103379A patent/AR037089A1/es active IP Right Grant
- 2002-09-06 UY UY27436A patent/UY27436A1/es not_active IP Right Cessation
2004
- 2004-02-16 JP JP2004038919A patent/JP2004210794A/ja active Pending
- 2004-03-02 IL IL160691A patent/IL160691A/en active IP Right Grant
- 2004-03-04 NO NO20040948A patent/NO327041B1/no not_active IP Right Cessation
- 2004-03-04 IS IS7170A patent/IS7170A/is unknown
- 2004-04-06 CO CO04032561A patent/CO5570671A2/es not_active Application Discontinuation
2007
- 2007-03-01 CY CY20071100289T patent/CY1106348T1/el unknown

Also Published As

Publication number	Publication date
HUP0401196A2 (hu)	2004-10-28
EP1427423B1 (en)	2006-12-27
WO2003022286A1 (en)	2003-03-20
KR20040036935A (ko)	2004-05-03
HK1065258A1 (en)	2005-02-18
IL160691A (en)	2011-11-30
CN1582151A (zh)	2005-02-16
KR100935623B1 (ko)	2010-01-07
ES2278045T3 (es)	2007-08-01
JP2004521961A (ja)	2004-07-22
EP1427423A1 (en)	2004-06-16
BR0212346A (pt)	2004-08-10
CO5570671A2 (es)	2005-10-31
IL160691A0 (en)	2004-08-31
DE60217136T2 (de)	2007-09-27
RU2004110716A (ru)	2005-05-10
CA2459449A1 (en)	2003-03-20
NO20040948L (no)	2004-03-04
AU2002329387B2 (en)	2007-06-07
DK1427423T3 (da)	2007-04-02
ATE349214T1 (de)	2007-01-15
JP3616635B2 (ja)	2005-02-02
MY131995A (en)	2007-09-28
EP1427423B9 (en)	2017-12-20
ES2278045T9 (es)	2018-04-23
DE60217136D1 (de)	2007-02-08
JP2004210794A (ja)	2004-07-29
CY1106348T1 (el)	2011-10-12
PL216023B1 (pl)	2014-02-28
RU2305681C2 (ru)	2007-09-10
AR037089A1 (es)	2004-10-20
DK1427423T5 (da)	2018-04-09
UY27436A1 (es)	2003-04-30
HU227623B1 (en)	2011-09-28
IS7170A (is)	2004-03-04
TWI331143B (en)	2010-10-01
NO327041B1 (no)	2009-04-06
NZ531796A (en)	2005-10-28
CA2459449C (en)	2011-02-01
US20050038009A1 (en)	2005-02-17
US7132416B2 (en)	2006-11-07
BRPI0212346B1 (pt)	2016-02-02
HUP0401196A3 (en)	2008-01-28
MXPA04002179A (es)	2004-06-29
PT1427423E (pt)	2007-03-30

Publication	Publication Date	Title
PL369078A1 (pl)	2005-04-18	Pochodne benzotiazepiny i benzotiadiazepiny mające aktywność hamowania transportu krętniczego kwasów żółciowych (IBAT) do leczenia hiperlipidemii
IL160503A0 (en)	2004-07-25	Benzothiazepine derivatives
IL160690A0 (en)	2004-08-31	Benzothiazepine ileal bile acid transport inhibitors
MY137508A (en)	2009-02-27	Chemical compounds
IL160689A0 (en)	2004-08-31	Benzothiazepine derivatives for treatment of hyperlipidemia
MY134270A (en)	2007-11-30	Peptides derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions
IL151296A0 (en)	2003-04-10	1,5-benzothiazepines and their use as hypolipidaemics
WO2003091232A3 (en)	2003-12-24	Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
GEP20064005B (en)	2006-12-25	Use of novel benzoimidazole derivatives as antiproliferative agents
CO5271691A1 (es)	2003-04-30	Nuevos compuestos
GEP20084357B (en)	2008-04-29	Pyrimidine derivatives for the treatment of abnormal cell growth
PL1685142T3 (pl)	2008-06-30	Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
HU9302933D0 (en)	1993-12-28	Heterocyclic compounds
SE0004811D0 (sv)	2000-12-21	Chemical compounds